Condition: Retinopathy · Retinal Vein Occlusion · Diabetic Retinopathy · Sponsor: MediBeacon
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
This description comes directly from the study's public registry record.
Richard B Dorshow, PhD · 314-735-0967 · rbdorshow@medibeacon.com
Always discuss trial participation with your own doctor first.
| University of Michigan Kellogg Eye Center | Ann Arbor, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04008121